Home / Market News / $DVA

$DVA news and market catalysts

The 16 most recent market catalysts affecting $DVA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

16 catalysts 2 high impact 9 bullish 4 bearish Healthcare Services
Nov 17, 2026 Corporate Catalyst Bullish Impact 55
DaVita Expands Availability of Advanced Dialysis Therapy to Every U.S. Center
DaVita announced the full rollout of its Expanded HD therapy across all U.S. centers, a significant operational expansion. This therapy utilizes advanced dialyzers to improve toxin…
Nov 2, 2026 Corporate Catalyst Bullish Impact 55
UBS Adjusts DaVita Price Target to $287
UBS updated its financial outlook for DaVita Inc., raising its price target from $270 to $287 and maintaining a 'Buy' rating. This indicates that UBS analysts see increased value i…
Nov 2, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Adjusts DaVita Price Target to $228
TD Cowen, a financial firm, adjusted its price target for DaVita Inc. (DVA) upwards from $220 to $228. This change indicates a slightly more favorable view of DaVita's stock value …
Oct 30, 2026 Corporate Catalyst Bearish Impact 75
DaVita CFO Comments on Medicare Add-on Payment Outlook
DaVita's CFO, Joel Ackerman, announced that Medicare add-on payments for the drug DefenCath are projected to drop significantly from Q1 2027 to Q2 2027 and remain low or continue t…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Barclays Adjusts DaVita Price Target
Barclays, a prominent financial institution, has adjusted its price target for DaVita Inc. (DVA) from $224 to $216. This change comes after DaVita's third-quarter 2026 earnings rep…
Oct 29, 2026 Corporate Catalyst Neutral Impact 92
DaVita Inc. Reports Third Quarter 2026 Financial Results
DaVita Inc. announced its third-quarter 2026 financial results, showcasing consolidated revenues of $3.578 billion, adjusted operating income of $561 million, and adjusted diluted …
Oct 26, 2026 Corporate Catalyst Bullish Impact 60
DaVita Announces Clinical Study Results for X9 System
DaVita announced positive results from the ACCESS-2 clinical study for the X9 System, an investigational device for hemodialysis needle placement. The study met its primary safety …
Oct 21, 2026 Corporate Catalyst Bullish Impact 55
DaVita Responds to HHS Kidney Care National Plan
DaVita (DVA) has publicly responded to the HHS national plan for kidney care, affirming its commitment to innovation, access, and patient choice. This filing is a corporate communi…
Oct 20, 2026 Corporate Catalyst Neutral Impact 75
'HHS releases new kidney care plan' - Axios Exclusive
The Axios article, acting as the filing content, reveals a new HHS kidney care plan focused on promoting home-based dialysis and transplants. This is a significant development beca…
Sep 4, 2026 Corporate Catalyst Bearish Impact 65
DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack
DaVita Inc. has reached a preliminary settlement agreement in a class-action lawsuit following a ransomware attack in April 2025 that compromised the personal and health informatio…
Aug 25, 2026 Corporate Catalyst Bullish Impact 55
DaVita Enters Value-Based Care Agreement With Humana Medicare Advantage To Provide Care To Members With Chronic Kidney Disease Stages 3B–5
DaVita (DVA) has announced an expansion of its value-based care partnership with Humana (HUM) to address chronic kidney disease (CKD) stages 3B-5 for over 10,000 Medicare Advantage…
Aug 5, 2026 Corporate Catalyst Bearish Impact 75
DaVita shares are trading lower after the company reported Q2 financial results. The company disclosed a quarter-over-quarter decline in its revenue per treatment.
The decline in DaVita's revenue per treatment is a significant concern as it directly impacts the company's top-line growth and profitability. This metric is crucial for healthcare…
Aug 4, 2026 Corporate Catalyst Neutral Impact 55
DaVita Form4 Filing Shows Berkshire Hathaway Sells 182,980 Davita Shares At An Average $199.55/Share, Still Owns About 28.7M Shares
Berkshire Hathaway, a prominent institutional investor, reported selling 182,980 shares of DaVita at an average price of $199.55 per share. While any sale by a major investor like …
Aug 4, 2026 Corporate Catalyst Bearish Impact 75
DaVita shares are trading lower after the company reported Q2 financial results. The company disclosed a quarter-over-quarter decline in its revenue per treatment.
The decline in DaVita's revenue per treatment is a significant concern for investors, as it directly impacts the company's top-line growth and profitability. This metric is a key i…
Aug 4, 2026 Corporate Catalyst Bullish Impact 92
DaVita Q2 Adj. EPS $4.02 Beats $3.88 Estimate, Sales $3.554B Beat $3.496B Estimate
DaVita's Q2 earnings of $4.02 per share significantly beat the analyst consensus of $3.88, representing a substantial 36.27% increase year-over-year. Similarly, quarterly sales of …
Jul 14, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Hold on DaVita, Raises Price Target to $250
Truist Securities analyst David Macdonald maintained a 'Hold' rating on DaVita (DVA) but raised the price target from $205 to $250. This action suggests that while the analyst sees…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.